Litigation Details for Pharmacyclics LLC v. Cipla Limited (D. Del. 2018)
✉ Email this page to a colleague
Pharmacyclics LLC v. Cipla Limited (D. Del. 2018)
| Docket | ⤷ Sign Up | Date Filed | 2018-02-01 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | Defendant | Referred To | Christopher J. Burke |
| Parties | TEVA PHARMACEUTICALS USA, INC. | ||
| Patents | 10,106,548; 10,125,140; 10,294,231; 8,754,090; 9,296,753; 9,725,455 | ||
| Attorneys | Neal C. Belgam | ||
| Firms | Morris, Nichols, Arsht & Tunnell | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Pharmacyclics LLC v. Cipla Limited
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Pharmacyclics LLC v. Cipla Limited (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-02-01 | 1 | Patent”); 8,476,284 (“the ’284 Patent”); 8,754,090 (“the ’090 Case 1:18-cv-00192-CFC Document 1 Filed… United States Patent Nos. 8,008,309 (“the ’309 Patent”); 7,514,444 (“the ’444 Patent”); 8,697,711 (“…(“the ’711 Patent”); 8,735,403 (“the ’403 Patent”); 8,957,079 (“the ’079 Patent”); 9,181,257 (“the ’257…’257 Patent”); 8,754,091 (“the ’091 Patent”); 8,497,277 (“the ’277 Patent”); 8,952,015 (“the ’015 Patent…37 PageID #: 2 Patent”); 9,296,753 (“the ’753 Patent”); 9,725,455 (“the ’455 Patent”); 9,540,382 (“the | External link to document | |
| 2019-02-14 | 104 | B2 ;9,801,881 B2 ;9,801,883 B2 ;10,125,140 B1 ;10,106,548 B2. (fms) (Entered: 02/14/2019) 14 February… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,296,753 B2 ;… 1 February 2018 1:18-cv-00192 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document | |
| 2019-03-15 | 128 | Answer to Counterclaim | Admitted. 17. U.S. Patent No. 10,106,548 (“the ’548 Patent”), on its face, is titled “Crystalline…’753 Patent, the ’455 Patent, the ’382 Patent, the ’617 Patent, the ’090 Patent, the ’889 Patent, the…’753 Patent, the ’455 Patent, the ’382 Patent, the ’617 Patent, the ’090 Patent, the ’889 Patent, the…’753 Patent, the ’455 Patent, the ’382 Patent, the ’617 Patent, the ’090 Patent, the ’889 Patent, the…753 Patent, the ’455 Patent, the ’382 Patent, the ’617 Patent, the ’090 Patent, the ’889 Patent, the | External link to document |
| 2019-05-29 | 163 | Complaint - Amended | (“the ’889 Patent”); 10,125,140 (“the ’140 Patent”); 10,106,548 (“the ’548 Patent”); and 10,016,435…expiration of U.S. Patent Nos. 9,296,753 (“the ’753 Patent”); 9,725,455 (“the ’455 Patent”); 9,540,382 … (“the ’382 Patent”); 9,713,617 (“the ’617 Patent”); 8,754,090 (“the ’090 Patent”); 9,125,889 Case 1:… 1. This action for patent infringement, brought pursuant to the patent laws of the United States…23. This civil action for patent infringement arises under the patent laws of the United States, | External link to document |
| 2019-08-08 | 210 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,294,231 B2 ;10,294,232 B2 … 1 February 2018 1:18-cv-00192 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| 2019-08-08 | 211 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,294,231 B2 ;10,294,232 B2 … 1 February 2018 1:18-cv-00192 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| 2019-08-08 | 212 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,294,231 B2 ;10,294,232 B2 … 1 February 2018 1:18-cv-00192 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
